Anal cancer treated with radio-chemotherapy: correlation between length of treatment interruption and outcome.
OBJECTIVE
The purpose of this study was the evaluation of the feasibility and outcome of definitive radio-chemotherapy without split-course technique but with individualised short treatment interruption in anal cancer patients.


METHODS
Between 1993 and 2008, 101 patients with anal cancer were treated in our institution with definitive radio-chemotherapy with individualised short treatment interruptions. Treatment was halted independent of dose in case of acute grade 3 toxicities and started again until improvement. Short interruption was defined as completing treatment without exceeding six cumulative treatment days beyond a scheduled plan; otherwise, it was defined as prolonged interruption.


RESULTS
Median overall treatment time was 47 days corresponding to an interruption of six cumulative treatment days. Fifty-one patients (50%) had treatment interruption of <or=6 days. No acute grade 4 toxicities were observed. One fatality occurred during treatment due to ileus-like symptoms according to acute grade 5 toxicity. After a median follow-up of 56 months, the 5-year actuarial rates for local control comparing patients with short vs. prolonged treatment interruption were 78% vs. 81% (p = 0.904) and, for colostomy-free survival, 83% vs. 85% (p = 0.784), respectively.


CONCLUSIONS
Definitive radio-chemotherapy with short individualised treatment interruption shows high local control and colostomy-free survival rates.
Janssen
Stefan
S
Department of Radiation Oncology, Medical School Hannover, Hannover, Germany. janssen.stefan@mh-hannover.de
Meier zu Eissen
Jürgen
J
Kolbert
Gerd
G
Bremer
Michael
M
Karstens
Johann Hinrich
JH
Meyer
Andreas
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001005:Anus Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents